QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rallybio-completes-dosing-for-first-cohort-in-phase-1-confirmatory-pkpd-study-of-rlyb116-its-once-weekly-small-volume-subcutaneous-c5-inhibitor-being-developed-to-treat-rare-diseases

Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative...

 rallybio-q2-eps-022-beats-024-estimate-sales-212000k-down-from-299000k-yoy

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 1...

 why-is-microcap-rallybio-stock-trading-higher-on-tuesday

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and mi...

Core News & Articles

Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced th...

 rallybio-initiates-dosing-in-phase-1-confirmatory-pkpd-study-evaluating-rlyb116-subcutaneously-injected-c5-inhibitor

– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refracto...

 rallybio-q1-eps-021-beats-026-estimate-sales-21200k

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 1...

 jones-trading-downgrades-rallybio-to-hold

Jones Trading analyst Catherine Novack downgrades Rallybio (NASDAQ:RLYB) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION